Adverse Events After Recombinant Human BMP2 in Nonspinal Orthopaedic Procedures

摘要

BackgroundThe FDA has approved recombinant human bone morphogenetic protein 2 (rhBMP-2) for treating acute, open tibial shaft fractures. However, the nature and frequency of complications after the use of rhBMP-2 in nonspinal orthopaedic surgery have not been well characterized.